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Abstract: In this work, the acridine nucleus was used as a lead-compound for structural 
modification by adding different substituted thiosemicarbazide moieties. Eight new  
(Z)-2-(acridin-9-ylmethylene)-N-phenylhydrazinecarbothioamide derivatives (3a–h) were 
synthesized, their antiproliferative activities were evaluated, and DNA binding properties 
were performed with calf thymus DNA (ctDNA) by electronic absorption and fluorescence 
spectroscopies. Both hyperchromic and hypochromic effects, as well as red or blue shifts 
were demonstrated by addition of ctDNA to the derivatives. The calculated binding 
constants ranged from 1.74 × 104 to 1.0 × 106 M−1 and quenching constants from  
−0.2 × 104 to 2.18 × 104 M−1 indicating high affinity to ctDNA base pairs. The most 
efficient compound in binding to ctDNA in vitro was (Z)-2-(acridin-9-ylmethylene)-N- 
(4-chlorophenyl) hydrazinecarbothioamide (3f), while the most active compound in 
antiproliferative assay was (Z)-2-(acridin-9-ylmethylene)-N-phenylhydrazinecarbothioamide 
(3a). There was no correlation between DNA-binding and in vitro antiproliferative activity, 
but the results suggest that DNA binding can be involved in the biological activity 
mechanism. This study may guide the choice of the size and shape of the intercalating part 
of the ligand and the strategic selection of substituents that increase DNA-binding or 
antiproliferative properties. 
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1. Introduction 
DNA has a strong affinity for many heterocyclic aromatic compounds; hence studies of the interaction 
between DNA and new chemotherapeutic agents play a key role in the fight against cancer [1]. DNA 
recognition is a critical step in the antitumor action of DNA intercalators. Given that intercalation 
constitutes a pivotal step in several clinically used anti-cancer drugs such as anthracyclines, acridines, 
and anthraquinones [2], understanding how small molecules interact with DNA is crucial for the 
formulation of more powerful and selective anticancer agents [3]. 
The synthesis of acridine and analogues has attracted considerable attention from organic and 
medicinal chemists for many years [4]. Amsacrine (m-AMSA) is an anticancer agent that displays 
activity against refractory acute leukemia as well as Hodgkin and non-Hodgkin’s lymphomas. The 
drug is comprised of an intercalative acridine moiety coupled to a 4'-amino-methanesulfon-m-anisidide 
head group. m-AMSA is historically significant in that it was the first drug demonstrated to function as 
a topoisomerase II poison. Although m-AMSA was designed as a DNA binding agent, much of its 
activity and specificity as topoisomerase II poison is embodied in the head group, while DNA 
intercalation is used primarily to increase the affinity of m-AMSA for the topoisomerase II-DNA 
cleavage complex [5]. Furthermore, DNA binding studies indicate that m-AMSA binds to DNA both 
by intercalation and by minor groove binding [6]. 
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Although m-AMSA is a DNA-intercalator and inhibitor of topoisomerase II, its metabolism may be 
associated with the production of free radicals, which causes serious damage in both cancer cells and 
normal tissues. For this reason, its clinical use is limited and researchers have been seeking to make 
further chemical modifications to m-AMSA by changing the nature of the 9-anilino substituent and the 
substituent pattern on the aniline and acridine nuclei, leading to a range of new m-AMSA-like 
derivatives [7]. It is worthwhile noting that the replacement of the acridine moiety with the analogous 
2-oxo-2H-pyrano[2,3-b]quinolone system yielded m-AMSA-like compounds that showed drastically 
reduced anticancer activity as well as an ability to intercalate into double stranded DNA (dsDNA) [8]. 
One strategy that has been used for the synthesis of new acridine derivatives involves combining 
the acridine ring with a different and independently acting moiety into one covalently linked hybrid 
compound, using for example the thiazolidine or imidazolidine nucleus [9]. As Barros et al. [10] have 
demonstrated, synthesizing new acridine-thiazolidine derivatives causes a distortion of the double 
helix of dsDNA. Concerning the cytotoxicity activity, the thiazacridines were selective for solid tumor 
cell lines. On the other hand, Lafayette et al. [9] provided insight into the DNA binding mechanism of 
imidazacridine and thiazacridine derivatives suggesting both intercalation and external binding. 
Thiosemicarbazone derivatives exhibit important biological activities [11], such as antibacterial [12], 
antimalarial, [13] and antitumor activities [14]. The antiproliferative properties of thiosemicarbazones 
have been attributed to their ability to chelate metal ions because of the presence of an NNS  
(Nitrogen–Nitrogen–Sulfur) tridentate set of donor atoms that bind not only iron, but also copper [15–17], 
molybdenum [18], nickel [16,19], zinc [17,19], and ruthenium [20]. The thiosemicarbazone-metal 
complexes are lipophilic and pass through the cell membrane to release the metal intracellularly. The 
free chelator can then complex with intracellular iron that can subsequently pass through the cell 
membrane mobilizing it out of the cell [21]. Besides, thiosemicarbazone antiproliferative activity can  
be due to DNA binding and cleavage, apoptosis induction, and cell enzyme inhibition [22,23].  
The small molecule chelator 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP; Triapine®, 
Nanotherapeutics, Alachua, FL, USA) inhibits the ribonucleotide reductase and prevents the replication 
of tumor cells by blocking a critical step in DNA synthesis [24]. This molecule is under Phase 2 
clinical trials evaluation for the treatment of solid tumors such as cervical and vaginal cancers [25]. 
Recently, several kinds of thiosemicarbazone derivatives were synthesized and their antitumor 
activities were also reported [26–30]. Geng et al. [31] used the anthracyclines as lead-compounds for 
structural modification by adding thiosemicarbazide to the anthraquinone ring. (E)-2-((1,4-Dihydroxy-
9,10-anthraquinone-2-yl)methylene)-N-(4-fluorophenyl)hydrazinecarbothioamide (DAFPT) was successfully 
synthesized and its interaction with ctDNA showed groove binding and preference for A–T rich 
regions. It was expected that this structural modification might overcome drug resistance and decrease 
the cardiotoxicity of anthracyclines. 
In this work, the acridine nucleus was used as a lead-compound for structural modification by 
adding different substituted thiosemicarbazide moieties. This paper describes the synthesis,  
DNA binding properties using ctDNA, as well as the antiproliferative activity of novel  
acridine-thiosemicarbazone derivatives.  
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2. Results and Discussion 
2.1. Chemistry 
The reaction sequence used for the synthesis of novel acridine-thiosemicarbazone compounds is 
shown in Scheme 1. The compound 9-methylacridine (1) was prepared from diphenylamine with zinc 
dichloride in acetic acid according to Tsuge et al. [32]. Subsequently, the oxidation of 1 with 
pyridinium chlorochromate (PCC) was accomplished according to Mosher and Natale [33] yielding  
9-acridinaldehyde (2). Compound 2 was used as starting reagent in the synthesis of different types of 
acridine-thiosemicarbazone derivatives. Thiosemicarbazides were synthesized in good yields (>90%) 
by adding hydrazine hydrate to different aryl isothiocyanates as previously described [34]. Thus, 
condensation of different thiosemicarbazide derivatives with 9-acridinaldehyde afforded the 
corresponding acridine-thiosemicarbazone derivatives 3a–h (Scheme 1). 
All known compounds (1, 2 and thiosemicarbazides) were identified by comparison with literature 
data. All new compounds (3a–h) were characterized by 1H-NMR, 13C-NMR, high-resolution mass 
spectrometry and infrared spectroscopy (Figures S1–S16 and Table S2). 
 
Scheme 1. Synthesis of acridine-thiosemicarbazone derivatives. Reagents and conditions: 
(i) pyridinium chlorochromate (PCC); (ii) EtOH, CH3COOH, reflux, 70 °C. 
2.2. DNA Binding Studies 
The absorption spectra of the new acridine-thiosemicarbazone derivatives 3a–h show that all 
compounds displayed absorption bands in the region of 300–500 nm. The different donor or acceptor 
substituents present in compounds 3c–h induced red shifts on UV–Vis spectra relative to that of 3a, 
with exception of 3f. In order to examine the general affinity of the derivatives 3a–h to dsDNA,  
the binding interactions of these ligands with calf thymus DNA (ctDNA) were examined by 
spectrophotometric titrations. It is widely accepted that if the compounds can bind to DNA, their  
UV–Vis curves result in a characteristic shift of the absorption maximum wavelength (bathochromic or 
hypsochromic shift) and a decrease (hypochromicity) [35,36] or increase (hyperchromicity) of the 
absorbance [9]. The absorption spectra of 3a (50 µM) in both the absence and presence of ctDNA  
(0–120 µM) are given in Figure 1 (for the other derivatives see Figures S17–S23). The curve shows 
significant hyperchromicity (92.58% at 120 µM of ctDNA) and a slight bathochromic shift (Δλ 6 nm) 
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with increasing ctDNA concentration, indicating a complex 3a-DNA formation. In the presence of 
ctDNA, all compounds (3a–h) produced hyperchromic or hypochromic effects, with the highest 
hypochromism being induced by the 3f derivative (Table 1). With the exception of compound 3g, all 
complexes with ctDNA showed bathochromic or hypsochromic effects with the most remarkable shifts 
for derivatives 3a and 3h, 6 and 12 nm, respectively. 
 
Figure 1. Absorption spectra of derivative 3a (50 µM) with increasing concentrations of 
calf thymus DNA (ctDNA). [DNA] = 0, 10, 20, 40, 60, 80, 100 and 120 µM. Arrows (↑) 
and (→) refer to hyperchromic, and bathchromic effects, respectively. Inset: Plot of 
[DNA]/(εa − εf) as function of DNA concentration as determined from the absorption 
spectral data. 
Table 1. UV–Vis absorption and fluorescence emission data of new acridine-thiosemicarbazone 
derivatives in the absence and presence of ctDNA. 
Compound 
λmax 
Absent 
(nm) 
λmax 
Present 
(nm) 
Extinction 
Coefficient 
(ε, M−1) 
Δλ 
(nm) 
Hypochr. 
(%) a 
Hyperchr. 
(%) b 
Kb (M−1) 
λ 
Excitation 
(nm) 
λ 
Emission 
(nm) 
KSV c (M−1) 
3a 360 366 7.300 6 – 92.58 3.77 × 105 359 439 0.92 × 104 
3b 375 372 8.600 3 – 28.13 1.84 × 105 370 441 −0.2 × 104 
3c 376 375 13.780 1 20.32 – 1.2 × 105 370 440 0.18 × 104 
3d 375 371 14.040 4 4.69 – 1.74 × 104 370 441 0.87 × 104 
3e 375 371 8.760 4 – 25.22 6.5 × 104 361 441 −0.27 × 104 
3f 357 358 14.860 1 39.59 – 1.0 × 106 355 440 2.18 × 104 
3g 362 362 9.200 0 – 24.4 9.91 × 104 352 439 0.5 × 104 
3h 383 371 11.546 12 11.54 – 8.47 × 105 350 439 1.75 × 104 
a Hypochromicity for complexes formed by compounds (3a–h) and 120 µM of ctDNA in comparison to  
free ligands; b Hyperchromicity for complexes formed by compounds (3a–h) and 120 µM of ctDNA in 
comparison to free ligands; c Stern–Volmer quenching constant, KSV, obtained from fluorimetric titrations 
with ctDNA. 
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After compound intercalation into the DNA base pairs, the π orbitals of the intercalated compounds 
are able to couple with the π orbitals of the base pairs, thereby decreasing the π → π* transition 
energies [15]. These interactions result in the observed hypochromism that is predictive of 
intercalation [37]. Besides this, the hypochromic effect and the red shift of the absorption maximum 
are characteristic of the association of a ligand with DNA [38] which is similar to the interaction 
recently observed for ctDNA and thiazacridine [9]. These results indicate that the acridine ring has an 
important role in the DNA interaction process [8] and confirm that both hyperchromic and 
hypochromic effects, as well as red or blue shifts reflect different degrees of DNA helix structure 
changes [39]. 
Absorbance intensity changes were used to calculate the DNA binding constants (Kb) of the 
acridine-thiosemicarbazone derivatives according to McGhee and von Hippel (Table 1) [40]. The 
calculated Kb ranged from 1.74 × 104 to 1.0 × 106 M−1, proves a high affinity of the new  
acridine-thiosemicarbazone derivatives for ctDNA base pairs. Typical Kb for intercalation complexes 
between organic dyes and DNA range from 1 × 104 to 1 × 106 M−1 and are usually significantly 
smaller than the binding constants of groove binders (1 × 105 to 1 × 109 M−1) [41]. The Kb values 
increased as follows: 3d < 3e < 3g < 3c < 3b < 3a < 3h < 3f. The high Kb presented by 3f suggests  
a strong binding towards ctDNA. 
Acridine substitution with thiosemicarbazone moiety influenced positively the intercalation power 
of the new derivatives since amsacrine-DNA link analysis has shown that the binding constant of the 
formed complex was Kb = 1.2 × 104 M−1, indicating weak or moderate strength of binding between 
them [6]. The binding constants of 3,6-bis(3-alkylguanidino)acridines with ctDNA investigated by 
UV–Vis and fluorescence spectroscopies, were estimated to range from 1.25 × 105 to 5.26 × 105 M−1 
and the percentage of hypochromism was found to be 17%–42% (from spectral titration) [42]. DNA 
binding constant studies of N-(9-acridinylthiocarbamoyl) amino acids (glycine, proline, leucine, 
histidine, phenylalanine, and tryptophan) derivatives by UV–Vis spectrophotometry, fluorescence 
titration, and quantum chemical calculation revealed that the lowest binding affinity was observed for  
N-(9-acridinylthiocarbamoyl)glycine (K = 1.4 × 105) and the highest for N-(9-acridinylthiocarbamoyl) 
tryptophan (K = 2.9 × 106) [43]. 
Herein, the highest Kb value (1.0 × 106) was demonstrated by the chloro-substituted derivative 3f. 
This result indicates that a chloro substituent affects positively the ability of a ligand to bind to ctDNA, 
since it can increase the ligand’s hydrophobic properties. In addition, the chloro atom leads to a 
slightly changed dipole of the ligand, thus increasing dipole–dipole interactions in the binding site, and 
it may even operate as a hydrogen-bond acceptor [44]. Derivative 3h presented the second highest Kb 
value (8.47 × 105), this finding supports the idea that intercalative π-stacking interactions of the ligands 
with DNA are essential for their efficient electron transfer reaction. Moreover, uniformity of Kb 
magnitudes for different substituted acridine rings validates the assumption that the DNA binding 
mechanism is heavily dependent on a common structural component of all studied systems, that is, the 
acridine skeleton, while its lateral substituents influence binding to a much lesser extent [45]. 
Spectrofluorimetric studies were also performed to analyze the binding properties between  
acridine-thiosemicarbazone derivatives and ctDNA. Table 1 summarizes the fluorescence emission 
from the derivatives under investigation (excitation and emission spectra can be seen in Figures S24–S31). 
Compounds 3a–h exhibited an emission band in the range of 400–500 nm. Excitation wavelengths were 
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at 350–370 nm and spectra were monitored at a fixed concentration of 15 µM of each derivative and 
different ctDNA concentrations. The fluorescence of acridine-thiosemicarbazone derivatives was quenched 
upon addition of ctDNA, except for 3b and 3e derivatives that exhibited an increase in their fluorescence 
intensity upon DNA addition. In general, the enhancement of fluorescence intensity may be explained 
by a significant suppression of the conformational flexibility of the ligand within the DNA–ligand 
complex [38]. Figure 2 presents the emission spectra of 3a in the presence of different concentrations of 
ctDNA (for the other derivatives see Figures S32–S38). 
 
Figure 2. Fluorescence spectra of derivative 3a (15 µM) with increasing concentrations of 
ctDNA. [DNA] = 0 (black), 10 (red), 20 (green), 40 (yellow), 60 (blue), 80 (pink),  
100 (light blue) and 120 (gray) µM. Arrow (↓) refers to hypochromic effect. 
The efficiency of the quenching process was deduced from the plot of the relative emission 
intensity, I0/I, vs. the DNA concentration (Figure 3) [46]. According to the resulting Stern–Volmer 
quenching constants, KSV, the most pronounced quenching was demonstrated by 3f derivative  
(2.18 × 104 M−1). KSV values decreased as follows: 3f > 3h > 3a > 3d > 3g > 3c > 3e > 3b. The 
emission intensity of the derivatives is quenched upon addition of DNA, most likely due to an efficient 
electron transfer between the excited ligand and the ctDNA bases. Emission-quenching phenomena 
reflect the interaction between the derivatives and ctDNA, consistent with the electronic absorption 
spectroscopy results [47]. Both Stern–Volmer (KSV) and binding constants (Kb) of the derivatives 
indicate static quenching due to complex formation by the new derivatives and ctDNA. The results 
indicate that the most efficient compound in binding to ctDNA in vitro was 3f (39.59% hypochromism 
and the highest Kb, KSV values). 
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Figure 3. Relative fluorescence intensities of acridine-thiosemicarbazone derivatives  
3a (●), 3b (◊), 3c (▲), 3d ( ), 3e (♦), 3f (○), 3g (□) and 3h (▼), upon addition of ctDNA 
in Tris buffer (0.01 M, pH = 7.6). 
According to fluorescence emission studies of the interaction of ctDNA and 3ʹ-azido-daunorubicin 
thiosemicarbazone performed by Cui et al. [48], the increasing amounts of ctDNA caused fluorescence 
intensity decrease without apparent shift of maximum fluorescence emission wavelength, which 
indicated the ctDNA binding. Interaction evaluation of DAFPT and ctDNA by competitive DNA 
binding assay demonstrated that DAFPT induced a fluorescence intensity decrease of ctDNA-ethidium 
bromide complex, probably through displacement of intercalated ethidium bromide from the adjacent 
base pairs of ctDNA [31]. These results demonstrated that thiosemicarbazone groups do not impair the 
DNA binding properties of other well established intercalators such as daunorubicin and the 
anthraquinone ring. In this work, the new acridine-thiosemicarbazones were able to interact with 
ctDNA since both the “light up” and “light off” effects were observed in fluorescence emission spectra. 
2.3. Antiproliferative Activity of 3a–h 
To determine the antiproliferative properties of the derivatives 3a–h, their in vitro antitumoral 
activities were assessed using nine different human tumor cell lines: glioma (U251), leukemia (K-562), 
breast (MCF7), breast resistant (NCI-ADR), kidney (786-O), lung (NCI-460), ovarian (OVCAR), 
prostate (PC-3), and colon (HT-29) and a normal cell line of human keratinocyte (HaCat). The 
compounds were used at concentrations ranging from 0.25 to 250 mg/mL; doxorubicin (DOX) and  
m-AMSA were used as positive controls. The analysis of cell growth inhibition (GI) was performed 
using the sulforhodamine B (SRB) assay. The anti-cancer activity (µM) of a tested compound was 
given by two parameters for each cell line: GI50 (molar concentration of the compound that inhibits 
50% cell growth) and TGI (molar concentration of the compound leading to total inhibition of the cell 
growth) [49]. 
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The type of side chain influences the cytotoxic activities of acridine derivatives [50]. For  
acridine-thiosemicarbazone derivatives, the nature of the substituent on the phenyl ring significantly 
influenced the antiproliferative activity (Table 2). The most active derivative was 3a as demonstrated 
in Figure 4 (for the other derivatives see Figures S39–S45). Compound 3a inhibited the growth of all cell 
lines in a dose-dependent manner, with GI50 values lower than 10 µM for all tumor cell lines. Tumor 
cell selectivity was not observed in the growth inhibition, but the pattern was similar to the positive 
control m-AMSA, also presented in Figure 4. However, the GI50 concentrations of 3a ranged widely from 
3- to 30-fold higher than those for m-AMSA. 
Notably, derivatives with electron-withdrawing (3f, 3g) and electron-donating substituents (3c, 3d 
and 3e) presented a dramatic decrease in antiproliferative activity as demonstrated by GI50 and TGI 
values (Table 2). Compound 3b bears an ethylene group as spacer between the nitrogen of the 
thiosemicarbazone moiety (acridine–C=N–N–C–(S)–N) and the phenyl ring that negatively influenced 
the antiproliferative activity when compared to 3a, as indicated by the difference in GI50 values 
(approximately 10-times higher). It was supposed that a high rotational freedom for the phenyl ring  
in 3b permitted substituent rotation negatively influencing its growth inhibition activity. Bulky 
substituents on the phenyl ring also caused a decrease of antiproliferative power, as can be seen from 
the GI50 and TGI values of the pair 3a and 3h. Derivative 3g presenting the 4-bromophenyl moiety 
exhibited selective cytostatic effects on OVCAR-3 cells. 
The lethal concentration LC50, represents the drug concentration required to kill 50% of the initial 
cell number, giving an idea of the cytotoxic action of the drug. Considering the LC50 (50% cell kill) 
values, compound 3a was lethal to NCI-H460, MCF-7, U251, NCI-ADR/RES, HT-29, and PC-3 cells 
at the respective concentrations: 43.41, 60.26, 68.93, 70.2, 70.24, and 72.95 µM. For the others cell 
lines, 3a LC50 concentrations were above 300 µM. 
 
Figure 4. Antiproliferative activity of 3a (concentrations of 0.7, 7.0, 70 and 702 µM) and 
amsacrine (m-AMSA) (concentrations of 0.6, 6.35, 63.5 and 635 µM) against nine 
cancerous cell lines: U251 (glioma, SNC); MCF-7 (breast adenocarcinoma);  
NCI-ADR/RES (ovary, multidrug resistance phenotype); 786-O (kidney); NCI-H460 (lung 
non-small cell adenocarcinoma); PC-3 (prostate); OVCAR-3 (ovary); HT-29 (colon);  
K-562 (Chronic myeloid leukemia) and human keratinocytes (HaCaT). 
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Table 2. GI50 and TGI (in µM) values for tested compounds 3a–h, doxorubicin (DOX) and amsacrine (m-AMSA) as positive controls. 
Compound
Cancer Cell Lines a 
U251 MCF-7 NCI-ADR 786-O NCI-H460 PC-3 OVCAR-3 HT-29 K-562 HaCaT 
GI50 TGI GI50 TGI GI50 TGI GI50 TGI GI50 TGI GI50 TGI GI50 TGI GI50 TGI GI50 TGI GI50 TGI 
3a 8.74 33.75 6.85 12.92 6.35 17.24 7.99 41.66 6.97 10.58 6.30 18.88 4.41 21.13 7.54 29.28 9.26 >100 4.17 51.42 
3b 80.84 >100 66.72 n.a. >100 n.a. 64.44 92.31 16.75 >100 73.74 >100 7.26 98.48 >100 n.a. n.a. n.a. >100 n.a. 
3c >100 n.a. 62.73 n.a. 62.94 n.a. 28.75 >100 8.63 n.a. 22.98 n.a. 8.38 >100 n.a. n.a. n.a. n.a. 7.00 >100 
3d n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
3e n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
3f >100 n.a. 27.19 >100 73.15 >100 >100 n.a. 28.36 n.a. 40.33 n.a. 62.41 >100 >100 n.a. 64.64 >100 >100 n.a. 
3g >100 n.a. n.a. n.a. n.a. n.a. >100 n.a. >100 n.a. 45.89 >100 0.98 65.7 n.a. n.a. n.a. n.a. n.a. n.a. 
3h >100 n.a. 69.24 n.a. 68.26 >100 >100 n.a. 70.37 n.a. 50.88 n.a. 71.39 >100 n.a. n.a. n.a. n.a. 70.06 n.a. 
DOX b 0.046 1.20 0.036 1.48 0.24 3.80 0.051 0.63 0.04 0.54 0.075 1.20 0.17 1.52 0.43 8.37 0.18 27.64 0.053 0.42 
m-AMSA 0.26 2.81 0.23 6.96 2.01 11.94 0.52 3.14 0.47 2.58 0.39 5.37 0.87 4.26 0.64 4.66 0.18 1.82 0.46 0.86 
a U251 (glioma, SNC); MCF-7 (breast adenocarcinoma); NCI-ADR/RES (ovary, multidrug resistance phenotype); 786-O (kidney); NCI-H460 (lung non-small cell 
adenocarcinoma); PC-3 (prostate); OVCAR-3 (ovary); HT-29 (colon); K-562 (Chronic myeloid leukemia); HaCaT (human keratinocytes); b Doxorubicin (DOX) was 
employed as the positive control. Cell lines were exposed to the compounds in DMSO/RPMI/FBS 5% at 37 °C, 5% CO2, for 48 h. n.a. = non-active at highest tested 
concentration (600 µM). 
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Even though there was no quantitative correlation between DNA-binding and in vitro activity,  
a lack of activity was observed for 3d and 3e, which possess the weakest Kb values, 1.74 × 104 and  
6.5 × 104, respectively, and the most active compound 3a presented the third highest Kb value  
(3.77 × 105). The chloro-substituted derivative 3f showed the highest Kb value, but its antiproliferative 
activity was dramatically lower than 3a and similar to other substituent groups that have essentially the 
same steric requirement such as methyl- and bromo-substituted derivatives, 3d and 3g respectively. 
Our findings suggest that the biological activity could be due to the interaction with DNA and/or to 
any other not studied mechanism. This study may guide the choice of the size and shape of the 
intercalating part of the ligand and the strategic selection of substituents that increase DNA-binding or 
antiproliferative properties. 
3. Experimental Section 
3.1. Materials and Methods 
The starting materials hydrazine hydrate, phenyl-, 4-tolyl-, 4-chlorophenyl-, 1-naphthyl-,  
4-bromophenyl-, 4-methoxyphenyl-, 4-ethylphenyl- and 2-phenylethyl-isothiocyanate were purchased 
from Sigma-Aldrich (Saint Louis, MO, USA) and were used as received for the synthesis of different 
thiosemicarbazides. Common solvents used for synthesis and analysis were supplied by Sigma-Aldrich 
(Saint Louis, MO, USA), Merck (Darmstadt, Germany) and Fluka (Buchs, SG, Switzerland) and used 
without purification. Melting points were measured in capillary tubes on a Quimis Model 340.27 
apparatus (Quimis, Diadema, Brasil). Thin Layer Cromatography (TLC) was performed on silica gel 
60 F254 plates from Merck (Darmstadt, Germany) with fluorescent detection at 254 nm. Infrared (IR) 
spectroscopy were recorded on a Bruker IFS66 spectrometer (Bruker, Berlin, Germany), using KBr 
pellets. The proton (1H-NMR) and carbon (13C-NMR) NMR experiments were performed on Varian 
Model Plus Spectrophotometer (Varian, Santa Clara, CA, USA) at 300 MHz, in DMSO-d6 as solvent. 
Mass spectra were recorded on matrix-assisted laser desorption/ionization recorded with a  
time-of-flight mass spectrometer (MALDI-TOF) Autoflex III (Bruker Daltonics, Billerica, MA, USA). 
UV–Vis spectra were measured on an Ultraspec 3000 PRO UV–Visible spectrophotometer (Biochrom 
Ltd., Cambridge, UK) and fluorescence spectra on a JASCO FP-6300 (Jasco Corporation, Tokyo, 
Japan) spectrofluorometer. 
3.2. General Preparation of the Acridine-Thiosemicarbazone Derivatives 3a–h 
The starting thiosemicarbazide (N-phenylhydrazinecarbothioamide;  
N-(4-chlorophenyl)hydrazinecarbothioamide; N-(naphtalen-1-yl)hydrazinecarbothioamide;  
N-(4-bromophenyl)hydrazinecarbothioamide; N-(4-methoxyphenyl)hydrazinecarbothioamide;  
N-phenethylhydrazinecarbothioamide; N-(4-ethylphenyl)hydrazinecarbothioamide and  
N-(p-tolyl)hydrazinecarbothioamide) were prepared according to the published procedures [34,51].  
Compound 2, 9-acridinaldehyde, (1.0 equivalent) and the thiosemicarbazide of choice (1.0 equivalent), 
were refluxed in ethanol (10 mL) in the presence of acetic acid (30 drops) and heated at 70 °C for 24 h. 
After this period, the mixture was filtered and washed with water and ethanol. 
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3.2.1. (Z)-2-(Acridin-9-ylmethylene)-N-phenylhydrazinecarbothioamide (3a) 
Yellow solid. Formula: C21H16N4S; M.W.: 356.44 g/mol; Melting point: 208–209 °C; Yield: 65%; 
Rf: 0.55 (n-hexane/EtOAc 7:3). 1H-NMR (300 MHz, DMSO-d6): δ 7.19 (t, 1H, phenyl, J = 7.5 Hz), 
7.36 (t, 2H, phenyl, J = 7.8 Hz), 7.60 (d, 2H, phenyl, J = 7.8 Hz), 7.72 (t, 2H, acridine, J = 8.4 Hz), 
7.89 (t, 2H, acridine, J = 8.4 Hz), 8.20 (d, 2H, acridine, J = 8.7 Hz), 8.61 (d, 2H, acridine, J = 8.7 Hz), 
9.39 (s, 1H, =CH), 10.23 (s, 1H, NH), 12.27 (s, 1H, NH). 13C-NMR: δ 123.3, 123.9, 124.9, 125.1, 
126.9, 127.9, 128.4, 129.5, 130.8, 130.2, 134.6, 138.8, 139.8, 148.1, 176.3. IR (cm−1): 3114 (C–H), 
3500 (NH), 1202 (C=S). MS (m/z): calculated = 357.1129; found = 357.124. 
3.2.2. (Z)-2-(Acridin-9-ylmethylene)-N-phenethylhydrazinecarbothioamide (3b) 
Yellow solid. Formula: C23H20N4S; M.W.: 384.49 g/mol; Melting point: 220–221 °C; Yield: 97%; 
Rf: 0.48 (n-hexane/EtOAc 8:2). 1H-NMR (400 MHz, DMSO-d6): δ 2.93 (t, 3H, J = 10.4 Hz, CH3), 3.80 
(q, 2H, J = 8.4 Hz, CH2), 7.27–7.18 (m, 5H, phenyl), 7.68 (t, 2H, J = 10.0 Hz, acridine), 7.88 (t, 2H,  
J = 9.6 Hz, acridine), 8.19 (d, 2H, J = 11.6 Hz, acridine), 8.49 (d, 2H, J = 10.8 Hz, acridine), 8.50  
(s, 1H, =CH–), 9.27 (s, 1H, NH), 11.86 (s, 1H, NH). 13C-NMR: δ 34.92, 45.67, 123.88, 125.66, 
125.66, 126.64, 126.64, 127.59, 127.59, 128.88, 128.88, 129.12, 129.12, 130.18, 130.18, 130.76, 
130.76, 135.48, 139.56, 139.68, 148.71, 148.71, 177.77. IR (cm−1): 3667.95 (NH), 3140.25 (NH), 
1520.45 (C=S). MS (m/z): calculated = 385.1442; found = 385.134. 
3.2.3. (Z)-2-(Acridin-9-ylmethylene)-N-(4-ethylphenyl)hydrazinecarbothioamide (3c) 
Pale green solid. Formula: C23H20N4S; M.W.: 384.49 g/mol; Melting point: 213–214 °C; Yield: 
98%; Rf: 0.6 (n-hexane/EtOAc 7:3). 1H-NMR (400 MHz, DMSO-d6): δ 1.18 (t, 3H, J = 7.2 Hz, CH3), 
2.57 (q, 2H, J = 7.2 Hz, CH2), 7.18 (d, 2H, J = 8.4 Hz, acridine), 7.48 (d, 2H, J = 8.4 Hz, acridine), 
7.71 (t, 2H, J = 7.2 Hz, acridine), 7.89 (t, 2H, J = 6.8 Hz, acridine), 8.20 (d, 2H, J = 8.8 Hz, phenyl), 
8.60 (d, 2H, J = 8.4 Hz, phenyl), 9.38 (s, 1H, =CH–), 10.08 (s, 1H, NH), 12.16 (s, 1H, NH). 13C-NMR: 
δ 15.66, 27.70, 123.47, 123.47, 125.33, 125.33, 125.40, 125.40, 127.16, 127.16, 127.38, 127.38, 
129.67, 129.67, 130.32, 130.32, 134.86, 136.57, 139.81, 140.91, 148.23, 148.23, 176.43. IR (cm−1):  
1536.91 (C=S), 2968.91 (=CH–), 3125.53 (NH), 3400.00 (NH). MS (m/z): calculated = 385.1442;  
found = 385.131. 
3.2.4. (Z)-2-(Acridin-9-ylmethylene)-N-(p-tolyl)hydrazinecarbothioamide (3d) 
Yellow solid. Formula: C22H18N4S; M.W.: 370.47 g/mol; Melting point: 119–221 °C; Yield: 90%; 
Rf: 0.55 (n-hexane/EtOAc 7:3). 1H-NMR (400 MHz, DMSO-d6): δ 2.29 (s, 3H, CH3), 7.15 (d, 2H,  
J = 8.4 Hz, acridine), 7.45 (d, 2H, J = 7.6 Hz, acridine), 7.71 (t, 2H, J = 7.6 Hz, acridine), 7.89 (t, 2H,  
J = 7.6 Hz, acridine), 8.20 (d, 2H, J = 9.2 Hz, phenyl), 8.60 (d, 2H, J = 8.4 Hz, phenyl), 9.38  
(s, 1H, = CH–), 10.01 (s, 1H, NH), 12.15 (s, 1H, NH). 13C-NMR: δ 20.56, 123.48, 123.48, 125.34, 
125.34, 125.37, 125.37, 127.16, 127.16, 128.56, 128.56, 129.68, 129.68, 130.32, 130.32, 134.55, 
134.89, 136.37, 139.80, 148.25, 176.48. IR (cm−1): 3671.99 (NH), 3129.28 (NH), 1534.92 (C=S). MS 
(m/z): calculated = 371.1286; found = 371.120. 
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3.2.5. (Z)-2-(Acridin-9-ylmethylene)-N-(4-methoxyphenyl)hydrazinecarbothioamide (3e) 
Yellow solid. Formula: C22H18N4OS; M.W.: 386.47 g/mol; Melting point: 219–220 °C; Yield: 82%; 
Rf: 0.43 (n-hexane/EtOAc 7:3). 1H-NMR (400 MHz, DMSO-d6): δ 3.76 (s, 3H, OCH3), 6.91 (m, 2H, 
acridine), 7.46 (m, 2H, acridine), 7.70 (m, 2H, phenyl), 7.87 (m, 2H, phenyl), 8.19 (m, 2H, acridine), 
8.60 (m, 2H, acridine), 9.38 (s, 1H, =CH–), 9.25 (s, 1H, NH), 12.02 (s, 1H, NH). 13C-NMR: δ 55.09, 
113.21, 113.21, 123.32, 123.32, 125.09, 125.09, 126.69, 126.69, 126.86, 126.86, 129.50, 129.50, 
129.99, 129.99, 131.69, 134.66, 139.57, 148.11, 148.11, 156.83, 176.67. IR (cm−1): 1514.52 (C=N), 
1533.44 (C=S), 3138.17 (NH), 3320.32 (NH). MS (m/z): calculated = 387.1235; found = 387.073. 
3.2.6. (Z)-2-(Acridin-9-ylmethylene)-N-(4-chlorophenyl)hydrazinecarbothioamide (3f) 
Yellow solid. Formula: C21H15ClN4S; M.W.: 390.88 g/mol; Melting point: 225–226 °C; Yield: 
86.5%; Rf: 0.54 (n-hexane/EtOAc 7:3). 1H-NMR (400 MHz, DMSO-d6): 7,40 (d, 2H, phenyl,  
J = 6.8 Hz), 7.63 (d, 2H, phenyl, J = 7.6 Hz), 7.72 (t, 2H, acridine, J = 7.2 Hz), 7.89 (t, 2H, acridine,  
J = 7.2 Hz), 8.21 (d, 2H, acridine, J = 9.2 Hz), 8.59 (d, 2H, acridine, J = 8.4 Hz), 9.39 (s, 1H, =CH–), 
10.23 (s, 1H, NH), 12.27 (s, 1H, NH). 13C-NMR: δ 123.3, 123.9, 124.9, 125.1, 126.9, 127.9, 128.4, 
129.5, 130.8, 130.2, 134.6, 138.8, 139.8, 148.1, 176.3. IR (cm−1): 3114 (C–H), 3500 (NH), 1202 
(C=S). MS (m/z): calculated = 391.0739; found = 391.041. 
3.2.7. (Z)-2-(Acridin-9-ylmethylene)-N-(4-bromophenyl)hydrazinecarbothioamide (3g) 
Yellow solid. Formula: C21H15BrN4S; M.W.: 435.34 g/mol; Melting point: 222–224 °C; Yield: 
82%; Rf: 0.45 (n-hexane/EtOAc 7:3). 1H-NMR (300 MHz, DMSO-d6): δ 7.56 (q, 4H, phenyl,  
J = 8.8 Hz), 7.75 (t, 2H, J = 8.4 Hz, acridine), 7.94 (t, 2H, J = 8.0 Hz, acridine), 8.23 (d, 2H, J = 8.8 Hz, 
acridine), 8.62 (d, 2H, J = 8.8 Hz, acridine), 9.40 (s, 1H, =CH–), 10.24 (s, 1H, NH), 12.31 (s, 1H, NH). 
13C-NMR: δ 117.60, 117.60, 123.52, 123.52, 123.52, 123.52, 125.51, 125.51, 127.34, 127.34, 127.45, 
127.45, 127.45, 127.45, 130.91, 130.91, 130.91, 138.38, 140.05, 140.05, 176.48. IR (cm−1): 3350.00 
(NH), 3128.54 (NH), 1539.02 (C=S). MS (m/z): calculated = 436.0180; found = 436.968. 
3.2.8. (Z)-2-(Acridin-9-ylmethylene)-N-(naphtalen-1-yl)hydrazinecarbothioamide (3h) 
Yellow solid. Formula: C25H18N4S; M.W.: 406.50 g/mol; Melting point: 208–210 °C; Yield: 32%; 
Rf: 0.55 (n-hexane/EtOAc 6:4). 1H-NMR (300 MHz, DMSO-d6): δ 7.49 (t, 2H, J = 8.1 Hz, acridine), 
7.58–7.54 (m, 3H, naphthyl), 7.61 (t, 2H, J = 8.4 Hz, acridine), 7.78–8.50 (m, 3H, naphthyl), 8.17  
(d, 2H, J = 7.8 Hz, acridine), 8.28–8.32 (m, 1H, naphthyl), 8.82 (d, 2H, J = 8.7 Hz, acridine), 9.51  
(s, 1H, =CH–), 10.49 (s, 1H, NH), 12.41 (s, 1H, NH). 13C-NMR: δ 157.95, 136.69, 133.85, 133.85, 
133.85, 128.29, 128.29, 127.59, 126.04, 126.04, 126.04, 126.04, 125.63, 125.63, 125.63, 125.27, 
125.27, 125.27, 123.56, 123.56, 122.69, 122.69, 121.91, 121.91, 115.37. IR (cm−1): 3309.48 (NH), 
3199.93 (NH), 1471.72 (C=S), 1212.81 (C–N). MS (m/z): calculated = 407.1286; found = 407.024. 
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3.3. UV–Vis Absorption Measurements 
UV–Vis spectra titrations were performed using 0.01 M Tris buffer, pH 7.6. Calf thymus DNA 
(ctDNA) was purchased from Sigma-Aldrich (Saint Louis, MO, USA) and used without further 
purification. The solution of ctDNA in Tris buffer was sonicated for 5 min and the DNA concentration 
was determined using the molar extinction coefficient 6600 M−1·cm−1 at 260 nm [52]. The DNA purity 
was determined by monitoring the value of the A260/A280 ratio. DNA concentration was expressed as 
micromolar equivalents of the base pairs. Acridine-thiosemicarbazone derivatives were dissolved in 
DMSO at a concentration of 1 mM (stock solution) from which working solutions of concentrations 
ranging from 10 to 50 μM were prepared by dilution using Tris buffer. After compound concentration 
optimization, ctDNA titration was performed with constant acridine derivative concentrations. All 
measurements were performed at 25 °C in a rectangular quartz cuvette with a 1 cm path length. The 
intrinsic binding constant (Kb) was obtained by fitting the data to Equation (1) [40]: 
[DNA]/(εa − εf) = [DNA]/(εb − εf) + 1/Kb (εb − εf) (1)
where εa, εb and εf are the apparent, bound with DNA, and free extinction coefficients of compounds, 
respectively. εa, εb and εf are all calculated from the Lambert–Beer’s law (ε = A/[compound]). Plot 
fitting of [DNA]/(εa − εf) vs. [DNA] used Kb obtained from the ratio of the slope to the y intercept.  
The binding data were fitted using the Origin 8.0® software (OriginLab Corporation, Northampton, 
MA, USA). 
3.4. Fluorescence Measurements 
Fluorescence measurements of non-bound derivatives were performed with solution concentration 
of 15 μM in 0.01 M Tris buffer, pH 7.6. Emission spectra were recorded in the region 380–600 nm 
using an excitation wavelength of 356–364 nm. All measurements were performed at 25 °C in a 
rectangular quartz cuvette with a 1 cm path length. Fluorescence intensities were expressed in arbitrary 
units. Fluorescence titrations were conducted by the addition of increasing amounts of ctDNA  
(0–120 μM bp) directly into the cell containing derivative solutions. Fluorescence intensities of 
compound solutions exposed to different ctDNA concentrations were used to calculate the Stern–Volmer 
constant, KSV, by the following Equation (2) [46]: 
F0/F = 1 + KSV[Q] (2)
where F0 and F are the steady-state fluorescence intensities of compounds in the absence and in the 
presence of quencher (ctDNA), KSV is the Stern–Volmer quenching constant, and [Q] is the 
concentration of quencher. 
3.5. Determination of Antiproliferative Activity 
Nine human cancer cell lines (U251 (glioma, CNS), MCF-7 (breast), NCI-ADR/RES (ovarian 
expressing phenotype multiple drugs resistance), 786-O (kidney), NCI-H460 (lung, non-small cells), 
PC-3 (prostate), OVCAR-03 (ovarian), HT-29 (colon adenocarcinoma) and K-562 (chronic myeloid 
leukemia)) and a normal cell line HaCat (human keratinocyte) were kindly provided by Frederick 
Cancer Research & Development Center, National Cancer Institute, Frederick, MA, USA. Stock 
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cultures were grown in 5 mL of RPMI-1640 (GIBCO, Carlsbad, CA, USA) supplemented with  
5% fetal bovine serum (FBS, GIBCO BRL). Penicillin: streptomycin mixture 1000 U/mL:1000 µg/mL 
(1 mL/L RPMI-1640) was added to experimental cultures. Cells in 96-well plates (100 µL cells/well, 
cell densities can be seen in Table S1) were exposed to different concentrations of samples (0.25, 2.5, 
25 and 250 µg/mL) in DMSO/RPMI/FBS 5% at 37 °C, 5% CO2, for 48 h. Final DMSO concentration 
did not affect cell viability. Cells were then fixed with trichloroacetic acid solution (50%, v/v) and cell 
proliferation was determined by spectrophotometric quantification (540 nm) of cellular protein content 
using sulforhodamine B assay [49]. Doxorubicin (DOX; 0.025–25 µg/mL) and m-AMSA at the same 
concentration were used as a positive control. Three measurements were obtained: at the beginning of 
incubation (T0) and 48 h post-incubation for compound-free (C) and tested (T) cells. The choice of  
48 h incubation was based on the NCI60 protocol, proposed by NCI/EUA for antiproliferative 
screening. Cell proliferation was determined according to the equation: 
Cell proliferation = 100 × [(T − T0)/C − T0] (3)
Cytostatic effect was observed when T0 ≤ T < C while cytocidal effect occurred when T < T0. From 
the concentration–response curve for each cell line, GI50, TGI, and LC50 values were determined 
through nonlinear regression analysis using the software Origin 8.0 (OriginLab Corporation). The 
experiments were done in triplicate. 
4. Conclusions 
Eight new (Z)-2-(acridin-9-ylmethylene)-N-phenylhydrazinecarbothioamide derivatives (3a–h) 
proved binding constants with ctDNA in the range 1.74 × 104 to 1.0 × 106 M−1 and quenching 
constants from −0.2 × 104 to 2.18 × 104 M−1 indicating high affinity to ctDNA base pairs. 
Combinations of hyperchromic or hypochromic effect and red or blue shifts were observed for most 
compounds, except for 3g derivative. The most efficient compound in binding to ctDNA in vitro was the 
chloro-substituted derivative 3f which was demonstrated by hypochromism, red shift and fluorescence 
quenching. On the other hand, the non-substituted phenyl ring derivative 3a showed the highest 
antiproliferative activity. In comparison with biochemical and biological properties (3a–h) produced in 
this study the following conclusions can be drawn: both binding constants with ctDNA and 
antiproliferative activities were influenced by substitution on the phenyl ring of thiosemicarbazone 
moieties since the most active compounds did not possess substitution (3a). There was no correlation 
between electron-withdrawing (3c, 3d and 3e) or electron-donating substituents on the phenyl ring  
(3f, 3g) and antiproliferativy activity, since both dramatically decreased this property. The results 
indicate that the coupling of the acridine ring and the thiosemicarbazide moiety yielded new  
acridine-thiosemicarbazone derivatives with promising DNA binding. However, the characteristics of 
substituents on the phenyl ring influence both the DNA-binding and the antiproliferative properties. 
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